A Phase IV, Multicentre, Open-label, Single-arm Study to Investigate the Efficacy, Safety and Durability of Faricimab (RO6867461) in Caucasian Patients With Polypoidal Choroidal Vasculopathy

The goal of this clinical trial is to assess the efficacy, safety and durability of faricimab in caucasian patients with polypoidal choroidal vasculopathy (PCV). The main question it aims to answer is:
To evaluate the efficacy of intravitreal (IVT) injections of faricimab 6 milligrams (mg) on Best Corrected Visual Acuity (BCVA) outcomes in caucasian patients with symptomatic macular PCV.
Participants will undergo ophthalmic examination, safety assessment and treatment with faricimab according to a patient specific treat and extend regimen.

Start Date01 Apr 2025

Sponsor / Collaborator

Association For Innovation & Biomedical Research

NCT06795048

/ RecruitingPhase 4

A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients With Neovascular Age-Related Macular Degeneration

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

Start Date14 Mar 2025

Sponsor / Collaborator-

NCT06790784

/ Not yet recruitingPhase 3IIT

A Randomized Clinical Trial Evaluating Combination Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of Proliferative Diabetic Retinopathy

This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.

Start Date01 Mar 2025

Sponsor / Collaborator

Jaeb Center For Health Research Foundation, Inc.

[+2]

100 Clinical Results associated with Faricimab

100 Translational Medicine associated with Faricimab

100 Patents (Medical) associated with Faricimab

291

Literatures (Medical) associated with Faricimab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan

Article

Author: Igarashi, Ataru ; Sakashita, Naotaka ; Shoji, Ayako ; Higashi, Kentaro ; Tsujimura, Jun ; Ohno, Shinya ; Yanagi, Yasuo

OBJECTIVE:

To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment.

METHODS:

A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). Further to treatment costs (public payer perspective), the societal burden (societal perspective), including costs of travel, informal care, and productivity, was assessed.

RESULTS:

In treatment of nAMD, lifetime quality-adjusted life years (QALYs) gained were highest with faricimab (faricimab T&E: 6.92, ranibizumab PRN: 6.88, ranibizumab T&E: 6.91, aflibercept T&E: 6.89, brolucizumab T&E: 6.89, BSC: 5.99). From the public payer perspective, the lifetime total cost for faricimab T&E was lower than those for ranibizumab (PRN, T&E) and brolucizumab (T&E), comparable to aflibercept T&E, and higher than BSC (incremental costs: 158,385 and 6,475,511 JPY, respectively). As a result, faricimab was cost-effective or dominant in the treatment of nAMD, excluding BSC. From the societal perspective, faricimab was dominant against all comparators in nAMD. In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.

CONCLUSIONS:

When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.

01 May 2025·CURRENT OPINION IN OPHTHALMOLOGY

Update on diagnosis and management of radiation retinopathy

Review

Author: Lovett, Eric A. ; Di Nicola, Maura ; Fan, Jason ; Williams, Basil K.

Purpose of review:

Radiation retinopathy is a vision-threatening complication of radiotherapy involving the eye or surrounding structures. This review aims to summarize recent advances in understanding the incidence, risk factors, pathophysiology, and utilization of new diagnostic imaging tools for radiation retinopathy. It will also focus on the current prophylaxis approaches to prevent or delay the development of radiation-related side effects and treatment strategies once radiation retinopathy occurs.

Recent findings:

The incidence of radiation retinopathy is influenced by radiation dose, fractionation schedule, and patient-specific factors such as diabetes mellitus and hypertension. Advances in imaging techniques, including optical coherence tomography angiography (OCTA) and ultra-widefield fluorescein angiography (UWFA), have enhanced early detection by identifying subclinical retinal changes. Novel insights into pathophysiology suggest a role for endothelial damage, inflammation, and oxidative stress in disease progression. Prophylactic approaches, such as intravitreal antivascular endothelial growth factor (anti-VEGF) agents, have shown promise in reducing the onset of retinopathy in high-risk patients. Therapeutic options, including intravitreal anti-VEGF and corticosteroids, have demonstrated efficacy in managing macular edema and preserving vision. However, the outcomes remain variable, necessitating personalized treatment strategies. To address some of these unanswered questions, the Diabetic Retinopathy Clinical Research Network (DRCR) Protocol AL is currently enrolling patients and preparing to analyze the long-term effects of treating patients prophylactically with intravitreal faricimab or the 0.19 mg fluocinolone acetonide implant compared to observation, to identify which patients will benefit from which specific regimen, therefore moving towards a personalized approach for this condition as well.

Summary:

Radiation retinopathy remains a significant challenge in ophthalmology. Early recognition through advanced imaging and tailored interventions, including prophylaxis and treatment, are crucial for optimizing visual outcomes. Further research into underlying mechanisms and novel therapies is essential to reduce the burden of this condition and improve patient quality of life.

01 May 2025·CURRENT OPINION IN OPHTHALMOLOGY

Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema

Review

Author: Kalavar, Meghana ; Sridhar, Jayanth

Purpose of review:

The goal of this review is to summarize emerging clinical trial and real world evidence for faricimab and high dose aflibercept (8 mg), two recently approved treatments for wet age-related macular degeneration and diabetic macular edema.

Recent findings:

Faricimab, a bispecific monoclonal antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2, and high-dose aflibercept have demonstrated significant potential for extending treatment intervals while maintaining efficacy. Pivotal clinical trials such as YOSEMITE, and RHINE established faricimab to be noninferior to standard anti-VEGF therapy with superior durability. Real-world data corroborated these results, demonstrating improved anatomic outcomes with extended treatment intervals, though improvements in best corrected visual acuity (BCVA) remains varied. High-dose aflibercept has similarly demonstrated noninferiority in landmark clinical trials such as PHOTON and PULSAR, with extended dosing intervals. However, comprehensive real-world data for high dose aflibercept remains limited and warrants further investigation.

Summary:

Both faricimab and high-dose aflibercept show promise in reducing treatment burden for wet age-related macular degeneration and diabetic macular edema through extended dosing intervals while maintaining or improving clinical outcomes compared to standard anti-VEGF therapy. Faricimab has demonstrated this both in clinical trials as well as real-world studies, while high-dose aflibercept has demonstrated similar durability in trials but requires additional real-world evidence.

247

News (Medical) associated with Faricimab

24 Mar 2025

·www.fiercebiotech.com

Speed, Scale, and Success – The Rise of Bispecific Antibodies in Targeted Therapies

None\n Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and rare diseases. According to Research and Markets, the bispecific antibody market is experiencing rapid growth, projected to rise from $12 billion in 2024 to $50 billion by 2030, driven by over 600 ongoing clinical trials.With the increasing demand for fast-tracked drug development, researchers and biopharmaceutical companies require high-quality bispecific antibodies delivered at high speed and scale. Biointron’s bispecific antibody production service addresses this need, providing customized, scalable solutions with a 2–3 week turnaround time.The Rise of Bispecific Antibodies: A New Era in Targeted TherapiesTraditional monoclonal antibodies (mAbs), primarily immunoglobulin G (IgG), are monospecific, recognizing and binding a single antigen. In contrast, bispecific antibodies are engineered to engage two distinct targets, enabling enhanced therapeutic mechanisms such as dual inhibition, immune cell redirection, and payload delivery. These properties make BsAbs highly effective in oncology, autoimmune diseases, and infectious disease therapies.Market Expansion and Clinical AdvancementsThe bispecific antibody sector has witnessed exponential growth, with 19 bispecific antibodies approved globally and total sales surpassing $35 billion as of March 2025. The expansion is fueled by breakthrough therapies such as:Hemlibra (emicizumab, Roche) – Approved in 2018, Emicizumab is a humanized, asymmetric bispecific IgG4 antibody that binds to blood clotting factor IXa and factor X. Emicizumab is used for the treatment of patients with hemophilia A, a hereditary bleeding disorder resulting from a deficiency of blood clotting factor VIII. This BsAb replicates the function of coagulation factor VIII by promoting the formation of the prothrombinase complex and subsequent clot formation.Vabysmo (faricimab, Roche) – Approved in 2022, Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) antibody that inhibits both Ang-2 and vascular endothelial growth factor A (VEGF-A). Through VEGF-A inhibition, Faricimab reduces endothelial cell proliferation, neovascularization, and vascular permeability. It was first approved to treat neovascular age-related macular degeneration, diabetic macular edema.One example of an emerging candidate under review is Regeneron’s Linvoseltamab, an investigational, fully human, BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.The US Leads in R&D and InnovationThe United States remains the global leader in bispecific antibody R&D and commercialization, with key players such as Roche, Amgen, Pfizer, and Johnson & Johnson having strong pipelines. Since 2015, the number of bispecific antibody clinical trials has surged from fewer than 100 to over 650 in 2025, highlighting the growing significance of BsAbs in modern medicine.Speed, Scale, and Success: Why Rapid Bispecific Antibody Development MattersThe Need for Speed in Drug DevelopmentWith bispecific antibody innovation accelerating, speed has become a critical factor in drug development. Pharmaceutical companies are under pressure to advance novel therapeutics through preclinical and clinical stages before competitors. Rapid antibody production allows researchers to:Optimize lead candidates efficiently through high-throughput screening.Accelerate preclinical studies to secure early-stage funding and partnerships.Meet IND application requirements with high-purity, functionally validated BsAbs.The Role of CROs in Expediting Bispecific Antibody DevelopmentAs bispecific antibody pipelines expand, biotech and pharmaceutical companies are increasingly outsourcing development to specialized contract research organizations (CROs). CRO partnerships provide:Rapid turnaround times that internal teams may struggle to achieve.Scalable production capabilities for large-scale research programs.Access to advanced antibody engineering technologies without in-house infrastructure constraints.Biointron’s Fast-Track Bispecific Antibody Production: A Game Changer2–3 Week Turnaround: Enabling Rapid Drug DiscoveryBiointron’s streamlined bispecific antibody production service provides high-quality BsAbs in just 2–3 weeks, significantly reducing preclinical development timelines. The optimized workflow includes:Gene Synthesis & Plasmid Preparation (1 week)Codon optimization for enhanced expression.Subcloning into proprietary high-expression vectors.Plasmid amplification and purification.Transient Expression & Purification (1–2 weeks)Mammalian cell-based expression for high-yield production.Affinity purification with stringent QC (SDS-PAGE purity >95%, endotoxin <1 EU/mg).Size-exclusion chromatography (SEC-HPLC) to confirm antibody integrity.Scalability and Customization for Any Research NeedsTo support the growing demand for bispecific antibodies, Biointron offers scalable solutions tailored to diverse research needs, including:Support for all bispecific formats – IgG-like, BiTE, DVD-Ig, and more.Automated production platforms for high-throughput antibody expression.Multiple purification methods ensuring consistent quality and reproducibility.Conclusion: The Future of Bispecific Therapies Requires Speed and ScaleBiointron’s fast-track bispecific antibody production service enables researchers to accelerate preclinical research, optimize therapeutic candidates, and bring life-changing therapies to market faster. Biointron has delivered over 10,000 bispecific antibodies to global biotech and pharmaceutical companies, offering industry-leading expertise in bispecific antibody engineering, consistent, high-purity production with rapid turnaround, and end-to-end support for researchers and drug developers.Would you like to find out more about antibody production?Visit Biointron’s Learning Center or contact our expert team at info@biointron.com or +1 (732) 790 - 8340.

ImmunotherapyDrug ApprovalADC

20 Mar 2025

·www.globenewswire.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respective holders of record at the close of business on April 3, 2025. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor contact:Juliane SnowdenXOMA Royalty Corporation+1-646-438-9754juliane.snowden@xoma.com Media contact:Kathy VincentKV Consulting & Management+1-310-403-8951kathy@kathyvincent.com

05 Feb 2025

·www.echemi.com

Roche Reports CHF 60.5 Billion Revenue in 2024 with Focus on Oncology and R&D Adjustments

On January 30, Roche announced its financial results for 2024, reporting total revenue of CHF 60.495 billion (approximately $66.4 billion with a conversion rate of 1 CHF = 1.0981 USD), representing a 7% year-on-year growth. However, net income declined to CHF 9.187 billion (about $10.1 billion), a significant drop of 19%. The company invested CHF 13.042 billion (around $14.3 billion) in research and development, accounting for 21.6% of total revenue. Oncology continued to be the primary focus for R&D, along with substantial investments in immunology, cardiovascular, renal, and metabolic fields. Roche's pharmaceutical business generated CHF 46 billion (about $50.7 billion), marking an 8% increase, while the diagnostics division saw revenues of CHF 14.3 billion (approximately $15.7 billion), up 7%. The pharmaceutical segment remains the main source of Roche's profits. The company's pharmaceutical portfolio includes targeted therapies across five key areas: oncology, immunology, neuroscience, hematology, and ophthalmology. The ophthalmology sector showed remarkable growth in 2024, with sales reaching CHF 4 billion, reflecting a 44% increase. All other therapeutic areas also maintained positive growth trajectories. The drug Vabysmo (faricimab), launched in early 2022, continued to be a major growth driver, with sales of CHF 3.864 billion (about $4.243 billion) driven by increasing demand across all regions. Vabysmo is approved for three major retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Looking ahead, Roche's pipeline is robust, featuring 71 new molecular entities (NMEs) and a total of 122 projects. However, the financial report indicated that the company has reduced ten projects in Q4 2024, primarily in early development stages. Notably, Roche made significant cuts to its TIGIT antibody RG6058 pipeline, including two Phase III trials, two Phase II trials, and one Phase I trial. Several early-stage projects were also removed from the pipeline, including: A Phase I study of the FAP/4-1BB bispecific antibody RG7827 for solid tumors. A Phase I study of the HER2/CD3 bispecific antibody RG6194 for breast cancer. Additional Phase I projects targeting various solid tumors. The TIGIT monoclonal antibody RG6058, which had been the first TIGIT antibody to enter Phase III trials globally. Roche also removed two Phase II trials for the TIGIT antibody targeting metastatic head and neck squamous cell carcinoma and non-small cell lung cancer, alongside two Phase III trials. In recent updates, Roche faced setbacks with the TIGIT antibody in 2024. The SKYSCRAPER-06 study, which evaluated the combination of tiragolumab, Tecentriq, and chemotherapy against pembrolizumab and chemotherapy for locally advanced non-squamous NSCLC, did not meet its primary endpoint, showing a hazard ratio of 1.27 for progression-free survival. Currently, Roche's TIGIT antibody pipeline includes five ongoing Phase III studies, focusing on NSCLC, esophageal cancer, and liver cancer. Looking forward, Roche anticipates the potential for over seven new molecular entities with peak sales exceeding CHF 3 billion, along with four additional entities with peak sales between CHF 2 billion and 3 billion.

Phase 1Drug ApprovalFinancial StatementPhase 2Phase 3

100 Deals associated with Faricimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11516	Faricimab	-	DB15303

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Retinal vein occlusion-related macular edema	Australia	Roche Products Pty Ltd.	08 Aug 2022
Age Related Macular Degeneration	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Choroidal Neovascularization	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Dystrophy, Macular	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Diabetic macular oedema	United States	Genentech, Inc.	28 Jan 2022
Wet age-related macular degeneration	United States	Genentech, Inc.	28 Jan 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinal Vein Occlusion	NDA/BLA	United States	Roche Holding AG	09 May 2023
Proliferative retinopathy with diabetes mellitus	Phase 3	-	Genentech, Inc.	01 Mar 2025
Myopic choroidal neovascularization	Phase 3	China	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	China	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	Roche China Holding Ltd.	28 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04740931 (BALATON/COMINO, Pubmed \| Ophthalmol Retina)	Phase 3	Retinal vein occlusion-related macular edema	-	Faricimab 6.0 mg Q4W	vffkdcegnj(uarptbfjgq) = lkobouevbz bpdrscyejy (fpqaacvgkq, 16.9 - 19.4) View more	Positive	01 Mar 2025
				Aflibercept 2.0 mg Q4W	vffkdcegnj(uarptbfjgq) = jvstesbfac bpdrscyejy (fpqaacvgkq, 17.5 - 20.0) View more
CTR20222310 (SALWEEN, Company_Website) Manual	Phase 3	Polypoidal choroidal vasculopathy	135	Vabysmo (faricimab)	jakwlwohuz(erxlvtmzdy) = apltbluocj jvjejicyon (rltoffldol ) View more	Positive	27 Nov 2024
NCT04432831 (Rhone-X, CTgov)	Phase 3	Diabetic macular oedema	1,479	Faricimab PTI+Faricimab Q8W (Faricimab PTI (Prior Faricimab Q8W))	fzxojhzkvk = thawhvondd vahdgibbfg (pcusxvidgz, moxsvluehd - xnnwbfpitx) View more	-	30 Oct 2024
				Faricimab PTI+Faricimab (Faricimab PTI (Prior Faricimab PTI))	fzxojhzkvk = cfrbjzvbzq vahdgibbfg (pcusxvidgz, azyponzzwo - tkbjqmhoyj) View more
NCT05224102 (ELEVATUM, GlobeNewswire) Manual	Phase 4	Diabetic macular oedema	124	Vabysmo (from racial and ethnic groups that are often underrepresented)	uyslophzzb(gkrfhtwkeb) = funnbpphpm mxnrgphnnp (waxxrzesyb ) View more	Positive	18 Oct 2024
				Vabysmo (Hispanic and Latino participants)	uyslophzzb(gkrfhtwkeb) = qdxamrkmsi mxnrgphnnp (waxxrzesyb )
FARETINA-AMD (EURETINA2024) Manual	Not Applicable	Wet age-related macular degeneration	26,278	Faricimab	ldrmilesvb(tqkcnpxmrp) = vsemdvmhpy tbsjjralzr (bbikpupwvt, 16.4) View more	Positive	19 Sep 2024
				Faricimabpt	ldrmilesvb(tqkcnpxmrp) = dnvncxcfye tbsjjralzr (bbikpupwvt, 12.0) View more
NCT04597918 (ALTIMETER, EURETINA2024) Manual	Phase 2	Diabetic macular oedema First line	99	Faricimab 6 mg	rejmdbgpvj(zhxbzvsmaa) = cntditykrf vbhoqoncmp (blcruabtkr, 7.5 - 10.9) View more	Positive	19 Sep 2024
EURETINA2024 Manual	Not Applicable	Diabetic macular oedema	23	Faricimab	gjmfbhxzsg(okwoqysclg) = None of the patients had adverse events with faricimab drqdvmbsdj (jatlnczlwf ) View more	Negative	19 Sep 2024
EURETINA2024 Manual	Not Applicable	Diabetic macular oedema \| Wet age-related macular degeneration	127	faricimab (Treatment-naïve neovascular age-related macular degeneration (nAMD))	bgihajvebk(amuifnqpod) = dvkebhumwb gxprsbthzx (xlmrsxvdnz )	Positive	19 Sep 2024
				faricimab (Previously-treated neovascular age-related macular degeneration (nAMD))	bgihajvebk(amuifnqpod) = fszupwtwwy gxprsbthzx (xlmrsxvdnz )
EURETINA2024 Manual	Not Applicable	Panuveitis	3	Faricimabeal Faricimab	swcdmosnxi(nljkuykatn) = eobsplwqzu wdqrbijtqk (hzgygrdzxl )	Positive	19 Sep 2024
EURETINA2024 Manual	Not Applicable	Diabetic macular oedema	38	Intravitreal Faricimab	jhutdhsbin(kfljconmas) = qfqvhspuuk txvsfydyir (wygsxcezkv ) View more	Positive	19 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis